Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011, with the report dated July 12, 2011. The filing serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan notifications rather than financial performance results.
Material Changes
On July 12, 2011, the Administrators of the GlaxoSmithKline Performance Share Plan notified the Company of an increase in notional interests for various participants. This increase resulted from the notional re-investment of the dividend paid to shareholders on July 7, 2011. The transaction prices were 1366.50 pence per Ordinary share and $43.91 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- The filing reports a specific corporate action: the notional re-investment of dividends into the Performance Share Plan for directors and managers.
- Transactions were executed at a price of 1366.50 pence per Ordinary share and $43.91 per ADR.
- Participants include senior executives such as Mr. A P Witty, Dr. M M Slaoui, and Mr. S M Bicknell, among others.
- This document does not contain quarterly or annual financial results; investors should refer to Form 20-F or other earnings releases for financial data.